1. Home
  2. FPF vs URGN Comparison

FPF vs URGN Comparison

Compare FPF & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

FPF

First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

HOLD

Current Price

$17.86

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$18.65

Market Cap

922.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FPF
URGN
Founded
2013
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
922.1M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
FPF
URGN
Price
$17.86
$18.65
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$29.29
AVG Volume (30 Days)
133.1K
592.7K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
8.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
N/A
$127.17
Revenue Next Year
N/A
$73.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.32
$3.42
52 Week High
$19.75
$30.00

Technical Indicators

Market Signals
Indicator
FPF
URGN
Relative Strength Index (RSI) 44.46 49.30
Support Level N/A $18.37
Resistance Level $18.88 $20.44
Average True Range (ATR) 0.33 0.93
MACD 0.02 0.18
Stochastic Oscillator 49.24 75.52

Price Performance

Historical Comparison
FPF
URGN

About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: